论文部分内容阅读
洋地黄糖甙类已沿用一百多年,迄今在治疗非梗阻性快速心率的低排性心力衰竭病人中仍不失为有效药物,但通过现代技术手段的检测及临床观察,对其长期正性收缩作用已引起怀疑,其次是治疗剂量与中毒剂量的过于接近甚至重叠而产生毒性反应,在无血药浓度监测的情况下易致不良后果;多巴胺类药物虽具有正性收缩和血管扩张的双重作用,但至今尚无理想的口服制剂,不能用于慢性心力衰竭病人的长期维持治疗。近几年来,用化学合成方法已研制出一组非糖甙、非儿茶酚胺新型强心药物,既具有正性收
Digitalis glycosides have been used for more than 100 years, so far in the treatment of non-obstructive fast heart rate in patients with low-rank heart failure is still an effective drug, but through the detection of modern technology and clinical observation of its long-term positive contractions The role has caused the suspicion, followed by the therapeutic dose and poisoning dose too close to or even overlap and produce toxic reactions, blood concentration monitoring in the case of prone to cause adverse consequences; dopamine drugs, although positive systolic and vasodilative dual role , But so far no ideal oral preparation, can not be used for chronic maintenance treatment of patients with chronic heart failure. In recent years, with a chemical synthesis method has been developed a group of non-glycosides, non-catecholamines new cardiac drugs, both positive